Заключение
Из вышеизложенного можно сделать вывод о важной роли PCSK9 в патогенезе атеросклероза. Основное патогенетическое влияние PCSK9 заключается в усилении деградации рецепторов липопротеинов низкой плотности (рЛПНП). Эти открытия сделали возможным создание нового класса эффективных противолипидемических препаратов - ингибиторов PCSK9. Помимо значимого влияния на липидный метаболизм, есть доказательства участия PCSK9 в воспалительных реакциях, которые являются еще одним важным звеном в этиопатогенезе атеросклероза. PCSK9 также может использоваться в качестве биомаркера для диагностики и прогнозирования ИБС, оценки тяжести поражения коронарных артерий и выявления субклинических атеросклеротических изменений в сосудах. Однако с учетом немногочисленности подобных исследований есть необходимость дальнейшего изучения.
Библиографический список
1. Buja, L.M. Nikolai N Anitschkow and the lipid hypothesis of atherosclerosis / L. M. Buja // Cardiovascular Pathology. - 2014. - Vol. 23, № 3. - P. 183-184.
2. Goldstein, J. L. The LDL receptor. / J. L. Goldstein, M. S. Brown // Arteriosclerosis, Thrombosis, and Vascular Biology. - 2009. - Vol. 29. - P. 431-438.
3. Basak, A. Inhibitors of proprotein convertases / A. Basak // Journal of Molecular Medicine (Berlin, Germany). - 2005. - Vol. 83, № 11. - P. 844-855.
4. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC- 1): liver regeneration and neuronal differentiation / N. G. Seidah, S. Benjannet, L. Wickham, J. Marcinkiewicz, S. B. Jasmin, S. Stifani, A. Basak, A. Prat, M. Chretien // Proc. Natl. Acad. Sci USA. - 2003. - Vol. 100 (3). - P. 928-933.
5. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system / S. Poirier, A. Prat, E. Marcinkiewicz, J. Paquin, B. P. Chitramuthu, D. Baranowski, B. Cadieux, H. P. Bennett, N. G. Seidah // Journal of Neurochemistry. - 2006. - Vol. 98 (3). - P. 838-850.
6. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia / M. Abifadel, M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, A. Derre, L. Villeger, M. Farnier, I. Beucler, E. Bruckert, J. Chambaz, B. Chanu, J. M. Lecerf, G. Luc, P. Moulin, J. Weissenbach, A. Prat, M. Krempf, C. Junien, N. G. Seidah, C. Boileau // Nature Genetics. - 2003. - Vol. 34. - P. 154-156.
7. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree / K. M. Timms, S. Wagner, M. E. Samuels, K. Forbey, H. Goldfine, S. Jam- mulapati, M. H. Skolnick, P. N. Hopkins, S. C. Hunt, D. M. Shattuck // Human Genetics. - 2004. - Vol. 114, № 4. - P. 349-353.
8. Leren, T. P. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia / T. P. Leren // Clinical Genetics. - 2004. - Vol. 65, № 5. - P. 419-422.
9. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: longterm follow-up and treatment response / R. P. Naoumova, I. Tosi,
D. Patel, C. Neuwirth, S. D. Horswell, A. D. Marais, C. van Heyningen, A. K. Soutar // Arteriosclerosis, Thrombosis, and Vascular Biology. - 2005. - Vol. 25, № 12. - P. 2654-2660.
10. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease / M. Abifadel, J. P. Rabes, M. Devillers, A. Munnich, D. Erlich, C. Junien, M. Varret, C. Boileau // Human Mutation. - 2009. - Vol. 30 (4). - P. 520-529.
11. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia / M. Abifadel, M. Guerin, S. Benjannet, J. P. Rabes, W. Le Goff, Z. Julia, J. Hamelin, V. Carreau, M. Varret, E. Bruckert, L. Tosolini, O. Meilhac, P. Couvert, D. Bonnefont-Rousselot, J. Chapman, A. Carrie, J. B. Michel, A. Prat, N. G. Seidah, C. Boileau // Atherosclerosis. - 2012. - Vol. 223 (2). - P. 394-400.
12. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population / Y. Miyake, R. Kimura, Y. Kokubo, A. Okayama, H. Tomoike, T. Yamamura, T. Miyata // Atherosclerosis. - 2008. - Vol. 196 (1). - P. 29-36.
13. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles / G. D. Norata, K. Garlaschelli, L. Grigore, S. Raselli, S. Tramontana, F. Meneghetti, R. Artali, D. Noto, A. B. Cefalu, G. Buccianti, M. Averna, A. L. Catapano // Atherosclerosis. - 2010. - Vol. 208 (1). - P. 177-182.
14. The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan / L.A. Hsu, M. S. Teng, Y. L. Ko, C. J. Chang, S. Wu, C. L. Wang, C. F. Hu // Clinical Chemistry and Laboratory Medicine. - 2009. - Vol. 47 (2). - P. 154-158.
15. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 / J. C. Cohen, A. Pertsemlidis, I. K. Kotowski, R. Graham, C. K. Garcia, H. H. Hobbs // Nature Genetics. - 2005. - Vol. 37 (2). - P. 161-165.
16. Cohen, J. C. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease / J. C. Cohen, E. Boerwinkle, T. H. Jr. Mosley, H. H. Hobbs // The New England Journal of Medicine. - 2006. - Vol. 354 (12). - P. 1264-1272.
17. Al-Mohaissen, M. A. Statin-associated muscle adverse events: update for clinicians / M. A. Al-Mohaissen, M. J. Ignaszewski, J. Frohlich, A. P. Ignaszewski // Sultan Qaboos University Medical Journal. - 2016. - Vol. 16 (4). - P. e406-e415.
18. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management / E. S. Stroes, P. D. Thompson, A. Corsini, G. D. Vladutiu, F. J. Raal, K. K. Ray, M. Roden, E. Stein, L. Tokgozoglu, B. G. Nordestgaard, E. Bruckert, G. De Backer, R. M. Krauss, U. Laufs, R. D. Santos, R. A. Hegele, G. K. Hovingh, L. A. Leiter, F. Mach, W. Marz, C. B. Newman, O. Wiklund, T. A. Jacobson, A. L. Catapano, M. J. Chapman, H. N. Ginsberg ; European Atherosclerosis Society Consensus Panel // European Heart Journal. - 2015. - Vol. 36 (17). - P. 1012-1022.
19. Статин-ассоциированные мышечные симптомы: эпидемиология, факторы риска, механизмы развития и лечебная тактика / А. И. Дядык, Т. Е. Куглер, С. Р. Зборовский, Ю. В. Сулиман // Кардиология. - 2019. - Vol. 59 (5S). - P. 4-12.
20. Lambert, G. Molecular basis of PCSK9 function / G. Lambert, F. Charlton, K. A. Rye, D. E. Piper // Atherosclerosis. - 2009. - Vol. 203 (1). - P. 1-7.
21. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia / D. Cunningham, D. E. Danley, K. F. Geoghegan, M. C. Griffor, J. L. Hawkins, T. A. Subashi, A. H. Varghese, M. J. Ammirati, J. S. Culp, L. R. Hoth, M. N. Mansour, K. M. McGrath, A. P. Seddon, S. Shenolikar, K. J. Stutzman-Engwall, L. C. Warren, D. Xia, X. Qiu // Nat. Struct. Mol. Biol. - 2007. - Vol. 14 (5). - P. 413-419.
22. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol / D. E. Piper, S. Jackson, Q. Liu, W. G. Romanow, S. Shetterly, S. T. Thibault, B. Shan, N. P. Walker // Structure. - 2007. - Vol. 15. - P. 545-552.
23. Molecular basis for LDL receptor recognition by PCSK9 / H. J. Kwon, T. A. Lagace, M. C. McNutt, J. D. Horton, J. Deisenhofer // Proc. Natl. Acad. Sci USA. - 2008. - Vol. 105. - P. 1820-1825.
24. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice / T. A. Lagace, D. E. Curtis, G. Garuti, M. C. McNutt, S.W. Park, H. B. Prather, N. N. Anderson, Y. K. Ho, R. E. Hammer, J. D. Horton // J. Clin. Invest. - 2006. - Vol. 116 (11). - P. 2995-3005.
25. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database / S. E. Leigh, A. H. Foster, R. A. Whittall, C. S. Hubbart, S. E. Humphries // Ann. Hum. Genet. - 2008. - Vol. 72. - P. 485-498.
26. Strom, T. B. PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum / T. B. Strom, K. Tveten, T. P. Leren // The Biochemical Journal. - 2014. - Vol. 457 (1). - P. 99-105.
27. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications / S. Ben- jannet, D. Rhainds, J. Hamelin, N. Nassoury, N. G. Seidah // J. Biol. Chem. - 2006. - Vol. 281 (41). - P. 30561-30572.
28. Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage / J. Cameron, O. L. Holla, J. K. Laerdahl, M. A. Kulseth, K. E. Berge, T. P. Leren // Atherosclerosis. - 2009. - Vol. 203 (1). - P. 161-165.
29. The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion / C. Gustafsen, M. Kjolby, M. Nyegaard, M. Mattheisen, J. Lundhede, H. Buttenschon, O. Mors, J. F. Bentzon, P. Madsen, A. Nykjaer, S. Glerup // Cell Metabolism. - 2014. - Vol. 19 (2). - P. 310-318.
30. Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice / C. Chen, J. Li, D. J. Matye, Y. Wang, T. Li // J. Lipid. Res. - 2019. - Vol. 60 (3). - P. 539-549.
31. Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases / A. Gao, F. S. Cayabyab, X. Chen, J. Yang, L. Wang, T. Peng, Y. Lv // DNA Cell Biol. - 2017. - Vol. 36 (12). - P. 1050-1061.
32. Brown, M. S. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor / M. S. Brown, J. L. Goldstein // Cell. - 1997. - Vol. 89. - P. 331-340.
33. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2 / H. J. Jeong, H. S. Lee, K. S. Kim, Y. K. Kim, D. Yoon, S. W. Park // J. Lipid. Res. - 2008. - Vol. 49. - P. 399-409.
34. Horton, J. D. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver / J. D. Horton, J. L. Goldstein, M. S. Brown // J. Clin. Invest. - 2002. - Vol. 109. - P. 1125-1131.
35. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice / K. N. Maxwell, R. E. Soccio, E. M. Duncan, E. Sehayek, J. L. Breslow // J. Lipid. Res. - 2003. - Vol. 44. - P. 2109-2119.
36. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia / G. Dubuc, A. Chamberland, H. Wassef, J. Davignon, N. G. Seidah, L. Bernier, A. Prat // Arteriosclerosis, Thrombosis, and Vascular Biology. - 2004. - Vol. 24 (8). - P. 1454-1459.
37. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 / H. E. Careskey, R. A. Davis, W. E. Alborn, J. S. Troutt, G. Cao, R. J. Konrad // J. Lipid. Res. - 2008. - Vol. 49 (2). - P. 394-398.
38. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine / H. Li, B. Dong, S. W. Park, H. S. Lee, W. Chen, J. Liu // J. Biol. Chem. - 2009. - Vol. 284. - P. 28885-28895.
39. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters / B. Dong, M. Wu, H. Li, F. B. Kraemer, K. Adeli, N. G. Seidah, S. W. Park, J. Liu // J. Lipid. Res. - 2009. - Vol. 51. - P. 1486-1495.
40. Nishikido, T. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries / T. Nishikido, K. K. Ray // Front. Cardiovasc. Med. - 2019. - Vol. 5. - P. 199.
41. Koylan, N. Перспективы новой тактики липидснижающей терапии: клиническая эффективность и профиль безопасности ингибиторов пропроте- ин/конвертазы субтилизин/кексина типа 9 / N. Koylan, М. Н. Мамедов // Международный журнал сердца и сосудистых заболеваний. - 2016. - Т. 4, № 11. - С. 3-7.
42. Чаулин, А. М. Роль пропротеин конвертазы субтилизин/кексин типа 9 (pcsk-9) в метаболизме холестерина и новые возможности липидкорригующей терапии / А. М. Чаулин, А. Ю. Мазаев, А. Г. Александров // Международный научноисследовательский журнал. - 2019. - № 4-1 (82). - С. 124-126.
43. Park, S. W. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver / S. W. Park, Y.A. Moon, J. D. Horton // The Journal of Biological Chemistry. - 2004. - Vol. 279 (48). - P. 50630-50638.
44. Maxwell, K. N. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment / K. N. Maxwell, E. A. Fisher, J. L. Bres- low // Proc. Natl. Acad. Sci USA. - 2005. - Vol. 102 (6). - P. 2069-2074.
45. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue / A. Roubtsova, M. N. Mun- conda, Z. Awan, J. Marcinkiewicz, A. Chamberland, C. Lazure, K. Cianflone, N. G. Seidah, A. Prat // Arteriosclerosis, Thrombosis, and Vascular Biology. - 2011. - Vol. 31 (4). - P. 785-791.
46. Cross-talk between LOX-1 and PCSK9 in vascular tissues / Z. Ding, S. Liu, X. Wang, X. Deng, Y. Fan, J. Shahanawaz, R. J. Shmookler Reis, K. I. Varughese, T. Sawamura, J. L. Mehta // Cardiovasc. Res. - 2015. - Vol. 107 (4). - P. 556-567.
47. Ding, Z. LOX-1 deletion and macrophage trafficking in atherosclerosis / Z. Ding, A. M. Mizeracki, C. Hu, J. L. Mehta // Biochem. Biophys. Res. Commun. - 2013. - Vol. 440 (2). - P. 210-214.
48. Seidah, N. G. PCSK9: a key modulator of cardiovascular health / N. G. Seidah, Z. Awan, M. Chretien, M. Mbikay // Circ. Res. - 2014. - 114 (6). - P. 1022-1036.
49. Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors / K. Leander, A. Ma- larstig, F. M. Van't Hooft, C. Hyde, M. L. Hellenius, J. S. Troutt, R. J. Konrad, J. Ohrvik, A. Hamsten, U. de Faire // Circulation. - 2016. - Vol. 133 (13). - P. 12301239.
50. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies / N. A. Almontashiri, R. O. Vilmundarson,
N. Ghasemzadeh, S. Dandona, R. Roberts, A. A. Quyyumi, H. H. Chen, A. F. Stewart // PLoS One. - 2014. - Vol. 9 (9). - P. e106294.
51. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study / B. Cariou, P. Guerin, C. Le May, V. Letocart, L. Arnaud, B. Guy- omarch, M. Pichelin, V. Probst // Diabetes Metab. - 2017. - Vol. 43 (6). - P. 529-535.
52. Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients / S. Toth, J. Fedacko, T. Pekarova, Z. Hertelyova, M. Katz, A. Mughees, J. Kuzma, P. Stefanic, I. Kopolovets, D. Pella // Cardiol. Ther. - 2017. - Vol. 6 (2). - P. 281-289.
53. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease / S. Li, Y. L. Guo, R. X. Xu, Y. Zhang, C. G. Zhu, J. Sun, P. Qing, N. Q. Wu, L. X. Jiang, J. J. Li // Atherosclerosis. - 2014. - Vol. 234 (2). - P. 441-445.
54. The central role of Pcsk9 in septic pathogen lipid transport and clearance / K. R. Wal- ley, G. A. Francis, S. M. Opal, E. A. Stein, J. A. Russell, J. H. Boyd // Am. J. Respir. Crit. Care Med. - 2015. - Vol. 191 (11). - P. 1275-1286.
55. Pcsk9 is a critical regulator of the innate immune response and septic shock outcome /K. R. Walley, K. R. Thain, J. A. Russell, M. P. Reilly, N. J. Meyer, J. F. Ferguson, J. D. Christie, T. A. Nakada, C. D. Fjell, S. A. Thair, M. S. Cirstea, J. H. Boyd // Sci Transl. Med. - 2014. - Vol. 6 (258). - P. 258ra143.
56. Walley, K. R. Role of lipoproteins and proprotein convertase subtilisin/kexin type 9 in endotoxin clearance in sepsis / K. R. Walley // Curr. Opin. Crit. Care. - 2016. - Vol. 22 (5). - P. 464-469.
57. Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis. / D. J. Dwivedi, P. M. Grin, M. Khan, A. Prat, J. Zhou, A. E. Fox-Robichaud, N. G. Seidah, P. C. Liaw // Shock. - 2016. - Vol. 46 (6). - P. 672-680.
58. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels / N. Ferri, G. Tibolla, A. Pirillo, F. Cipollone, A. Mezzetti, S. Pacia, A. Corsini, A. L. Catapano // Atherosclerosis. - 2012. - Vol. 220 (2). - P. 381-386.
59. Prognostic value of PCSK9 levels in patients with acute coronary syndromes / B. Gencer, F. Montecucco, D. Nanchen, F. Carbone, R. Klingenberg, N. Vuilleumier, S. Aghlmandi, D. Heg, L. Raber, R. Auer, P. Juni, S. Windecker, T. F. Luscher, C. M. Matter, N. Rodondi, F. Mach // European Heart Journal. - 2016. - Vol. 37 (6). - P. 546-553.
60. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO- IVUS study / J. M. Cheng, R. M. Oemrawsingh, H. M. Garcia-Garcia, E. Boersma, R. J. van Geuns, P. W. Serruys, I. Kardys, K. M. Akkerhuis // Atherosclerosis. - 2016. - Vol. 248. - P. 117-122.
References
1. Buja L. M. Cardiovascular Pathology. 2014, vol. 23, no. 3, pp. 183-184.
2. Goldstein J. L., Brown M. S. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009, vol. 29, pp. 431-438.
3. Basak A. Journal of Molecular Medicine (Berlin, Germany). 2005, vol. 83, no. 11, pp. 844-855.
4. Seidah N. G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S. B., Stifani S., Basak A., Prat A., Chretien M. Proc. Natl. Acad. Sci USA. 2003, vol. 100 (3), pp. 928-933.
5. Poirier S., Prat A., Marcinkiewicz E., Paquin J., Chitramuthu B. P., Baranowski D., Ca- dieux B., Bennett H. P., Seidah N. G. Journal of Neurochemistry. 2006, vol. 98 (3), pp. 838-850.
6. Abifadel M., Varret M., Rabes J. P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D., Derre A., Villeger L., Farnier M., Beucler I., Bruckert E., Chambaz J., Chanu B., Lecerf J. M., Luc G., Moulin P., Weissenbach J., Prat A., Krempf M., Junien C., Seidah N. G., Boileau C. Nature Genetics. 2003, vol. 34, pp. 154-156.
7. Timms K. M., Wagner S., Samuels M. E., Forbey K., Goldfine H., Jammulapati S., Skolnick M. H., Hopkins P. N., Hunt S. C., Shattuck D. M. Human Genetics. 2004, vol. 114, no. 4, pp. 349-353.
8. Leren T. P. Clinical Genetics. 2004, vol. 65, no. 5, pp. 419-422.
9. Naoumova R. P., Tosi I., Patel D., Neuwirth C., Horswell S. D., Marais A. D., van Heyningen C., Soutar A. K. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005, vol. 25, no. 12, pp. 2654-2660.
10. Abifadel M., Rabes J. P., Devillers M., Munnich A., Erlich D., Junien C., Varret M., Boileau C. Human Mutation. 2009, vol. 30 (4), pp. 520-529.
11. Abifadel M., Guerin M., Benjannet S., Rabes J. P., Le Goff W., Julia Z., Hamelin J., Carreau V., Varret M., Bruckert E., Tosolini L., Meilhac O., Couvert P., Bonnefont- Rousselot D., Chapman J., Carrie A., Michel J. B., Prat A., Seidah N. G., Boileau C. Atherosclerosis. 2012, vol. 223 (2), pp. 394-400.
12. Miyake Y., Kimura R., Kokubo Y., Okayama A., Tomoike H., Yamamura T., Miyata T. Atherosclerosis. 2008, vol. 196 (1), pp. 29-36.
13. Norata G. D., Garlaschelli K., Grigore L., Raselli S., Tramontana S., Meneghetti F., Ar- tali R., Noto D., Cefalu A. B., Buccianti G., Averna M., Catapano A. L. Atherosclerosis. 2010, vol. 208 (1), pp. 177-182.
14. Hsu L. A., Teng M. S., Ko Y. L., Chang C. J., Wu S., Wang C. L., Hu C. F. Clinical Chemistry and Laboratory Medicine. 2009, vol. 47 (2), pp. 154-158.
15. Cohen J. C., Pertsemlidis A., Kotowski I. K., Graham R., Garcia C. K., Hobbs H. H. Nature Genetics. 2005, vol. 37 (2), pp. 161-165.
16. Cohen J. C., Boerwinkle E.,. Mosley T. H. Jr, Hobbs H. H. The New England Journal of Medicine. 2006, vol. 354 (12), pp. 1264-1272.
17. Al-Mohaissen M. A., Ignaszewski M. J., Frohlich J., Ignaszewski A. P. Sultan Qaboos University Medical Journal. 2016, vol. 16 (4), pp. e406-e415.
18. Stroes E. S., Thompson P. D., Corsini A., Vladutiu G. D., Raal F. J., Ray K. K., Roden M., Stein E., Tokgozoglu L., Nordestgaard B. G., Bruckert E., De Backer G., Krauss R. M., Laufs U., Santos R. D., Hegele R. A., Hovingh G. K., Leiter L. A., Mach F., Marz
W., Newman C. B., Wiklund O., Jacobson T. A., Catapano A. L., Chapman M. J., Ginsberg H. N.; European Atherosclerosis Society Consensus Panel European Heart Journal. 2015, vol. 36 (17), pp. 1012-1022.
19. Dyadyk A. I., Kugler T. E., Zborovskiy S. R., Suliman Yu. V. Kardiologiya [Cardiology]. 2019, vol. 59 (5S), pp. 4-12. [In Russian]
20. Lambert G., Charlton F., Rye K. A., Piper D. E. Atherosclerosis. 2009, vol. 203 (1), pp. 1-7.
21. Cunningham D., Danley D. E., Geoghegan K. F., Griffor M. C., Hawkins J. L., Subashi T. A., Varghese A. H., Ammirati M. J., Culp J. S., Hoth L. R., Mansour M. N., McGrath K. M., Seddon A. P., Shenolikar S., Stutzman-Engwall K. J., Warren L. C., Xia D., Qiu X. Nat. Struct. Mol. Biol. 2007, vol. 14 (5), pp. 413-419.
22. Piper D. E., Jackson S., Liu Q., Romanow W. G., Shetterly S., Thibault S. T., Shan B., Walker N. P. Structure. 2007, vol. 15, pp. 545-552.
23. Kwon H. J., Lagace T. A., McNutt M. C., Horton J. D., Deisenhofer J. Proc. Natl. Acad. Sci USA. 2008, vol. 105, pp. 1820-1825.